Aptose Biosciences — Investor Presentation (March 2025)
23 slides from Aptose Biosciences's investor presentation, Mar 12, 2025
Slide 1: Corporate Presentation March 2025
Aptose Precision oncology company developing oral targeted agents to treat hematologic malignancies C o r p o r a t e P r e s e n t a t i o n M a r c h 2025 Tuspetinib in Frontline Triple Drug Therapy to Treat Newly Diagnosed AML 1 NASDAQ: APTO TSX: APS
Slide 2: Tuspetinib as third agent for frontline AML
AML (Acute Myeloid Leukemia) • Highly aggressive and deadly cancer of the bone marrow and blood Current Frontline (1L) Standard of Care Therapy • VEN+AZA (Venetoclax + Azacitidine) two drug therapy • Survival too short | median Overall Survival <15mos • Too few patients achieve complete responses (C
Slide 3: Solution: TUS as Superior 3rd Agent
Solution: TUS as Superior 3 rd Agent Proof that Triplet Therapy Works with a Targeted Kinase Inhibitor ‒ Gilteritinib (Gilt) added to VEN+AZA boosts CR rate to 90% So, What’s the Problem: Gilt proves “Triplet Therapy” works, but has Limitations ‒ Gilt active in 30% of patients (harbor FLT3 mutation)
Slide 4: TUS+VEN+AZA Frontline Triplet: Clinical Data
4 TUS+VEN+AZA Frontline Triplet : Clinical Data (as of February 2025) ‒ TUSCANY Dose - Selection Study Initiated Dec 2024 ‒ Dosing Began with 40mg TUS and Escalated to 80mg TUS TUS+VEN+AZA TUSCANY Study Dose Selection │ 40mg, 80mg, + Safety, CR rate, MRD negativity, OS FLT3 WT (70% of cases) Most Co
Slide 5: 40mg TUS in Newly Diagnosed AML from TUSCANY Study
TUS+VEN+AZA Frontline Triplet Clinical Data (February 2025): 40mg TUS in Newly Diagnosed AML from TUSCANY Study 5 Safety of TUS+VEN+AZA Triplet with 40mg TUS • No prolonged myelosuppression of subjects in remission • No significant safety concerns or dose limiting toxicities (DLTs) • No dose reducti
Slide 6: Timelines: Financings, Clinical Trials, and Milestones
Q4 2024 ASH ASH EHA Triplet Frontline Therapy In Newly Diagnosed AML Timelines: Financings, Clinical Trials, and Milestones ASH EHA Q1 Q2 Q3 Q4 2025 Q1 Q2 Q3 Q4 2026 TUS+VEN+AZA Ph 1 Triplet Study Initiated 1L Triplet Dosing in Newly Diagnosed AML Multiple Reports of Response and Safety Data in 1L A
Slide 7: Aptose Leadership and KOL Advisors
AML : Acute Myeloid Leukemia ; TUS : Tuspetinib ; VEN : Venetoclax ; AZA : Azacitidine ; HMA : Hypomethylating agent ; SOC : Standard of Care ; CR : Complete Remission ; mOS : median overall survival 7 Aptose Leadership and KOL Advisors
Slide 8: Aptose Management Team
Aptose Management Team William G. Rice, PhD Chairman, President & Chief Executive Officer Rafael Bejar, MD, PhD Sr. VP & Chief Medical Officer KOL, Hematologic Malignancies Fletcher Payne Sr. VP, Chief Financial Officer & Chief Business Officer 8
Slide 9: Scientific Advisory Board
Scientific Advisory Board Brian Druker, M.D. Chair, Aptose Scientific Advisory Board Lead Investigator of Beat AML Initiative Daniel D. Von Hoff, M.D., F.A.C.P. Michael Andreeff, M.D., PhD. Stephen B. Howell, M.D. Ad Hoc AML Clinical Advisory Board Naval Daver, M.D. MD Anderson Cancer Center Chair 9
Slide 10: Investment Thesis: Hanmi Collaboration Reduces Investment Risk
Investment Thesis Hanmi Collaboration Reduces Investment Risk 10 • Hanmi - Aptose collaboration agreement (expected Q2/2025) planned to provide significant capital to fund the TUS Triplet Study • Hanmi's $10M advance being converted to common stock Proven Effectiveness of Frontline Triplet as Concep
Slide 11: Risk and Reward: Clinical Data, Milestones, Hanmi Collaboration
APTO Nasdaq Rebalancing Risk and Reward: Clinical Data, Upcoming Milestones, and the Planned Collaboration with Hanmi 11 Market Summary • ATM and CEF Established • Executed Reverse Stock Split • Planned financings and Hanmi Collaboration are earmarked to support TUS - based TUS+VEN+HMA Triplet devel
Slide 12: Aptose Disclosure
Aptose Disclosure 12 This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or invitation for the sale or purchase of, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities, businesses and/or as
Slide 13: Thank you
Thank you APTOSE BIOSCIENCES
Slide 14: Appendix
Appendix APTOSE BIOSCIENCES
Slide 15: Tuspetinib Development Path
AML : Acute Myeloid Leukemia ; TUS : Tuspetinib ; VEN : Venetoclax ; AZA : Azacitidine ; HMA : Hypomethylating agent ; SOC : Standard of Care ; CR : Complete Remission ; mOS : median overall survival 15 Tuspetinib Development Path Findings from the TUS Single Agent Trial and the TUS - VEN Doublet Tr
Slide 16: Completed TUS Single Agent and TUS+VEN Doublet in R/R AML
Completed TUS Single Agent and TUS+VEN Doublet in Prior Therapy Failure R/R AML Findings Supported Advancement to TUS+VEN+AZA Triplet TUSCANY Trial Cohort 1: 20 mg QD 2 Cohort 2: 40 mg QD 17 Cohort 3: 80 mg QD 20 Cohort 4: 120 mg QD 32 Cohort 5: 160 mg QD 16 Cohort 6: 200 mg QD 4 TUS Single Agent Do
Slide 17: TUS and TUS+VEN Clinical Findings in R/R AML Patients
TUS and TUS+VEN Clinical Findings in Highly Tx Experienced R/R AML Patients Safe and Well Tolerated | Achieve Bone Marrow Blast Reductions and Responses TUS Single Agent Once Daily Orally (n= 93 Pts) • Excellent Safety and Tolerability ‒ No drug - related myelosuppression in remission ‒ No drug - re
Slide 18: TUS and TUS+VEN Safe and Well Tolerated in R/R AML
TUS and TUS+VEN Safe and Well Tolerated in Highly Treatment Experienced R/R AML TUS+VEN Doublet TUS Single Agent Related to TUS/VEN, n(%) (n=79) Adverse Events Treatment Emergent AEs Related to VEN Treatment Emergent AEs Related to TUS Treatment Emergent AEs Treatment Related AEs Treatment Emergent
Slide 19: TUS Single Agent Bone Marrow Leukemic Blasts Percent Change
19 TUS Single Agent Treatment Bone Marrow Leukemic Blasts │Percent Change from Baseline Blast Reductions Demonstrate Activity Across 4 Dose Levels Activity in Patients Who Failed Prior - VEN and Prior - FLT3i Note: Blast percent change was calculated as 100 X (the lowest post - baseline bone marrow
Slide 20: Tuspetinib Precision Targeting Mechanism of Action
AML : Acute Myeloid Leukemia ; TUS : Tuspetinib ; VEN : Venetoclax ; AZA : Azacitidine ; HMA : Hypomethylating agent ; SOC : Standard of Care ; CR : Complete Remission ; mOS : median overall survival 20 Tuspetinib Precision Targeting Mechanism of Action
Slide 21: Tuspetinib Kinase Inhibition Profile
Tuspetinib Kinase Inhibition Profile – Unique Target Profile Suppresses key oncogenic signaling pathways Avoids targets that compromise safety 10nM Test Con centration >90% >75 - 89% >50 - 74% >25 - 49% HPK1 JAK2 JAK1 FLT1 MLK2 FGFR 3/4 FLT4 MLK3 MLK1 LRRK2 ABL RET PDGFR PDGFR β b YES LCK SRC EPHA7
Slide 22: TUS Targets Known VEN-Resistance Mechanisms
TUS Targets Known VEN - Resistance Mechanisms and May Minimize Drug Resistance FLT3 KIT MCL - 1 RAS/ MAPK SYK JAK/STAT PI3K/AKT TUS Tuspetinib: • Suppresses oncogenic signaling directly • Promotes cancer cell death signaling indirectly 22
Slide 23: Thank you
Thank you APTOSE BIOSCIENCES
Aptose Biosciences — Investor Presentation (March 2025) on 6ix